RPG Life Sciences Limited announced its audited financial results for the quarter and year ended March 31, 2026, following a Board meeting held on April 29, 2026. The company delivered robust performance with strong revenue growth and improved profitability metrics compared to the previous year.

Q4 Financial Performance

For the quarter ended March 31, 2026, the company reported revenue from operations of Rs 176.9 crore, compared to Rs 143.1 crore in the corresponding quarter of the previous year, representing a robust 23.6% year-on-year growth. EBITDA for the quarter increased 48.0% to Rs 45.2 crore from Rs 30.6 crore, with EBITDA margin improving to 25.6% from 21.4%.

Profit before tax (excluding exceptional items) grew 56.4% to Rs 39.1 crore from Rs 25.0 crore, while profit after tax (excluding exceptional items) increased 58.1% to Rs 29.3 crore from Rs 18.5 crore. PAT margin improved to 16.5% from 12.9%.

Full Year Performance

For the full year ended March 31, 2026, revenue from operations increased to Rs 707.5 crore from Rs 653.4 crore in the previous year, representing an 8.3% growth. EBITDA for FY26 stood at Rs 172.7 crore with a margin of 24.4%, compared to Rs 172.3 crore with a 26.4% margin in FY25. PAT (excluding exceptional items) was Rs 111.7 crore with a margin of 15.8%, versus Rs 111.6 crore with a 17.1% margin in the previous year.

Segment Performance and Business Highlights

The Domestic Formulations (DF) business, which contributes 69% to total sales, delivered market-beating growth of 18.2% in Q4 compared to the Indian Pharma Market (IPM) growth of 10.1%. For the full year FY26, the DF business recorded 13.7% growth versus IPM's 8.6%, driven by strong portfolio performance across key therapy baskets including nephrology, oncology, and pain management. DF sales reached Rs 483.5 crore in FY26 from Rs 425.0 crore in FY25.

The API division demonstrated a strong comeback with sales of Rs 95.1 crore in FY26 compared to Rs 90.2 crore in FY25, registering growth of 5.3%. This performance is notable considering the fire incident at the API manufacturing plant in Navi Mumbai in January 2025 and the timely restoration of the facility. The International Formulations business contributed 18% to total sales with revenue of Rs 123.4 crore in FY26.

Board Decisions and Corporate Actions

Dividend Recommendation

The Board of Directors recommended a final dividend of Rs 24 per equity share, equivalent to 300% on the face value of Rs 8 each for FY 2025-26. The dividend is subject to approval by shareholders at the ensuing Annual General Meeting and will be paid or dispatched within 30 days of such approval.

Director Appointment

Dr. Samdani is not related to any Director or Key Managerial Personnel of the company and brings extensive medical expertise to the Board.

Exceptional Items

The company reported exceptional items totaling Rs 110 lakh for the quarter ended March 31, 2026 and Rs 390 lakh for the full year. These included the net impact of insurance claims related to the fire incident at the API plant, which resulted in a net income of Rs 2,475 lakh for the year. The company also recorded an impact of Rs 1,169 lakh due to new Labour Codes and an impairment of Rs 916 lakh on intangible assets under development.

Strategic Priorities and Outlook

The company outlined six key strategic priorities including driving a purpose-led organization, scaling core brands like Naprosyn towards becoming a Rs 100 crore+ brand, building specialty and chronic portfolios, strengthening API business with improved operational resilience, expanding global presence, and embedding cost discipline and ESG-led practices. The company also reaffirmed its ICRA rating at A+ with stable outlook, highlighting its robust capital structure and debt-free status.

Regulatory Compliance

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published its audited financial results in Business Standard (English) and Mumbai Lakshadeep (Marathi) newspapers on April 30, 2026. The results are also available on the company's website at www.rpglifesciences.com .

RPG Life Sciences Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 2026. The certificate, issued by MUFG Intime India Private Limited on April 3, 2026, confirms the company's adherence to dematerialisation requirements and regulatory timelines.

SEBI Compliance Certificate Submission

The company filed the compliance certificate with stock exchanges on April 9, 2026, confirming that all securities received from depository participants for dematerialisation during the quarter ended March 31, 2026, were processed within prescribed timelines. The certificate validates that security certificates received for dematerialisation were properly mutilated and cancelled after verification.

Special Window for Physical Share Transfer

Concurrently, RPG Life Sciences has announced the opening of a special window for shareholders to lodge transfer and dematerialisation requests for physical securities that were sold or purchased prior to April 1, 2019. This initiative follows SEBI's regulatory directive and provides a limited-time opportunity for eligible shareholders to complete pending transfer processes.

The special window has been established pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The company published newspaper advertisements in Business Standard (English) and Mumbai Lakshadeep (Marathi) on April 7, 2026, to inform shareholders about this facility.

Eligibility and Processing Requirements

The special window facility applies to two specific scenarios: where original share transfer requests were not lodged prior to April 1, 2019, and the shareholder holds the original share certificate, or where original requests were lodged but rejected due to document deficiencies. Eligible requests can be submitted to MUFG Intime India Pvt. Ltd., the company's Registrar and Transfer Agent.

All shares processed through this special window will be mandatorily credited in dematerialised form only and will remain under lock-in for one year from the registration date. During the lock-in period, the securities cannot be transferred, lien-marked, or pledged.